Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fletikumab Mechanism of Action in RA
NCT02097264Phase 2Withdrawn
- Sponsor
- Novo Nordisk
- Start
- Sep 2014
- Primary completion
- Sep 2015
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of fletikumab in rheumatoid arthritis (RA), sponsored by Novo Nordisk. Planned start Sep 2014; status: withdrawn.
02
Drugs
fletikumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02097264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097264.